TSS
PLRX icon

Two Sigma Securities’s Pliant Therapeutics PLRX Stock Holding History

Two Sigma Securities’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,042
Closed -$14K – 1873
2025
Q2 		$14K Buy
+12,042
New +$17K ﹤0.01% 1274

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Two Sigma Securities's PLRX Position: Q3 2025 in Review

Two Sigma Securities sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 12,042 shares — an estimated $14K sold.

Two Sigma Securities first reported a position in PLRX in Q2 2025 and held it in 1 quarter. The position peaked at $14K in Q2 2025. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

  • Two Sigma Securities reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Securities sold 12,042 Pliant Therapeutics shares in Q3 2025, an estimated $14K.
  • Two Sigma Securities first reported a position in Pliant Therapeutics in Q2 2025 and held it in 1 quarter.
  • Two Sigma Securities's Pliant Therapeutics position peaked at $14K in Q2 2025.
  • 99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.